Abstract 12572: Low Incidence of Cardiovascular Events in Patients With Metastatic Sarcoma Using Upfront Dexrazoxane and High-Dose Doxorubicin

Joshua D. Mitchell,Brian A. Van Tine,Angela C. Hirbe,Peter Oppelt,Ashley Frith,Richa Rathore,Fei Wan,Shellie Berry,Michele Landeau,George A. Heberton,John Gorcsan,Peter Huntjens,Yoku Soyama,Justin M. Vader,Jose Alvarez-Cardona,Kathleen W. Zhang,Daniel J. Lenihan,Ronald J. Krone

Abstract 12572: Low Incidence of Cardiovascular Events in Patients With Metastatic Sarcoma Using Upfront Dexrazoxane and High-Dose Doxorubicin

2021

Joshua D. Mitchell
Brian A. Van Tine
Angela C. Hirbe
Peter Oppelt
Ashley Frith
Richa Rathore
Fei Wan
Shellie Berry
Michele Landeau
George A. Heberton
John Gorcsan
Peter Huntjens
Yoku Soyama
Justin M. Vader
Jose Alvarez-Cardona
Kathleen W. Zhang
Daniel J. Lenihan
Ronald J. Krone

Background: Prognosis for soft tissue sarcoma (STS) remains poor with a progression free survival of 4.6 months. Doxorubicin is a central and effective treatment option, though cardiotoxicity frequ...

Keywords:

Cardioprotection
Oncology
Progression-free survival
Doxorubicin
Incidence (epidemiology)
Soft tissue sarcoma
Internal medicine
Heart failure
Medicine
Dexrazoxane
Cardiotoxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations